A Phase 1/2 interventional study of AT-007 and Placebo in Classic Galactosemia, sponsored by Applied Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-30.
Sponsored by Applied Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a first-in-human, randomized, placebo-controlled, 4-Part, single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy adult subjects and adult subjects with Classic Galactosemia.
The study is designed to assess the safety and PK of AT-007 in healthy subjects and subjects with Classic Galactosemia as well as the effect of AT-007 on biomarkers of galactose metabolism (galactose, galactitol, and other galactose metabolites) in subjects with Classic Galactosemia.
This study consists of 4 parts:
Applied Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AT-007 is a CNS and retina penetrant aldose reductase inhibitor.
Drug: AT-007
Placebo is used as a comparator to the experimental arm.
Drug: Placebo
AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
Also known as: Govorestat
Matching placebo will be administered once in the morning before breakfast
Number of Participants With Treatment-emergent Adverse Events
To evaluate the safety and tolerability of AT-007 after administration to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.
Time frame: Events after 1 day of administration.
Number of Participants With Treatment-emergent Adverse Events
To evaluate the safety and tolerability of AT-007 after multiple ascending doses are administered to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results. Part B and Part C are combined.
Time frame: 7 Days after Dosing
Number of Participants With Treatment-emergent Adverse Events
To evaluate the safety and tolerability of AT-007 after multiple doses administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.
Time frame: 28 Days of Dosing
Number of Participants With Treatment-emergent Adverse Events
To evaluate the safety and tolerability of AT-007 administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.
Time frame: 90 Days after Dosing
Cmax of AT-007
Maximum (peak) plasma drug concentration
Time frame: Part A: Sampling- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs Parts B, C, D: Day of Last Dose for each Part- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs D Extension: Day 30, 60, 90- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs
Tmax of AT-007
Time to reach maximum (peak) plasma drug concentration
Time frame: Part A: Sampling- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs Parts B, C, D: Day of Last Dose for each Part- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs D Extension: Day 30, 60, 90- predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48 hrs
t1/2 of AT-007
Terminal elimination half life
Time frame: Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Parts B, C, D: Determined using Day of Last Dose for the respective Part; predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.
AUClast of AT-007
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration
Time frame: Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Parts B, C, D: Determined using Day of Last Dose for the respective Part at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.
AUCinf of AT-007
Area under the plasma concentration-time curve from time zero extrapolated to infinity
Time frame: Part A: Sequential sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours. Part D: Determined using Day 1 with sampling at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours.
Maximal Galactitol Reduction in Plasma
Disease-Specific Biomarker in Classic Galactosemia Patients
Time frame: Part D: Samples at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours on days 1, 12, 32. Part D Extension: Samples at predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 hours on days 1, 30, 60, & 90.
Galactose Concentration in Plasma
Disease-Specific Biomarker in Classic Galactosemia Patients
Time frame: Part D: Day 32. Part D Extension: Days 30, 60, & 90.
Galactose-1-Phosphate (Gal-1p) Concentration in Plasma
Disease-Specific Biomarker in Classic Galactosemia Patients
Time frame: Part D: Day 32. Part D Extension: Days 30, 60, & 90.
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Milestone | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator | Part B & C: AT-007 5mg/kg | Part B & C: AT-007 10mg/kg | Part B & C: AT-007 20mg/kg | Part B & C: AT-007 40mg/kg | Part B &C: Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D: Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension: Placebo Compartor |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
To evaluate the safety and tolerability of AT-007 after administration to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.
| Participants | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A: Placebo Comparator |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | 1 | 0 | 0 | 2 | 1 | 2 |
To evaluate the safety and tolerability of AT-007 after multiple ascending doses are administered to healthy subjects, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results. Part B and Part C are combined.
| Participants | Part B & C AT-007 5mg/kg Cohort | Part B & C AT-007 10mg/kg Cohort | Part B & C AT-007 20mg/kg Cohort | Part B & C AT-007 40mg/kg Cohort | Part B & C Placebo Comparator |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | 1 | 2 | 3 | 1 | 2 |
To evaluate the safety and tolerability of AT-007 after multiple doses administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.
| Participants | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | 3 | 1 | 2 | 2 |
To evaluate the safety and tolerability of AT-007 administered to Classic Galactosemia Patients, including clinically-significant changes in clinical laboratory test results, physical examination findings, vital sign evaluations, and electrocardiogram results.
| Participants | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: AT-007 40mg/kg | Part D Extension Placebo Comparator |
|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | 7 | 1 | 2 |
Maximum (peak) plasma drug concentration
| microgram/mL | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part B & C Cohort 1: AT-007 5mg/kg | Part B & C Cohort 2: AT-007 10mg/kg | Part B & C Cohort 3: AT-007 20mg/kg | Part B & C Cohort 4: AT-007 40mg/kg | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Extension Cohort 1: AT-007 20mg/kg DAY 30 | Part D Extension Cohort 1: AT-007 20mg/kg DAY 60 | Part D Extension Cohort 1: AT-007 20mg/kg DAY 90 | Part D Extension Cohort 2: AT-007 40mg/kg DAY 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax of AT-007 | 1.53 ± 55.2 | 8.92 ± 31.4 | 15.2 ± 49.5 | 27 ± 103 | 57.4 ± 23.2 | 15.2 ± 45.0 | 23.0 ± 39.0 | 47.8 ± 35.4 | 72.8 ± 44.9 | 13.7 ± 34.0 | 39.9 ± 70.8 | 67.9 ± 68.0 | 48.6 ± 21.8 | 48.0 ± 24.4 | 44.1 ± 36.5 | 70.8 ± NA |
Time to reach maximum (peak) plasma drug concentration
| hours | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part B & C Cohort 1: AT-007 5mg/kg | Part B & C Cohort 2: AT-007 10mg/kg | Part B & C Cohort 3: AT-007 20mg/kg | Part B & C Cohort 4: AT-007 40mg/kg | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Extension Cohort 1: AT-007 20mg/kg DAY 30 | Part D Extension Cohort 1: AT-007 20mg/kg DAY 60 | Part D Extension Cohort 1: AT-007 20mg/kg DAY 90 | Part D Extension Cohort 2: AT-007 40mg/kg DAY 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax of AT-007 | 4.00 (4.00 to 6.02) | 4.00 (2.00 to 4.00) | 4.00 (4.00 to 4.00) | 4.00 (4.00 to 24.1) | 4.00 (4.00 to 8.00) | 4.00 (4.00 to 8.00) | 3.96 (2.00 to 8.00) | 4.00 (4.00 to 8.00) | 4.00 (4.00 to 6.07) | 4.00 (2.00 to 6.00) | 4.96 (4.00 to 8.00) | 4.00 (1.92 to 8.00) | 4.03 (1.97 to 8.02) | 4.01 (2.00 to 7.97) | 4.00 (2.00 to 4.33) | 4.17 (4.17 to 4.17) |
Terminal elimination half life
| hours | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part B & C Cohort 1: AT-007 5mg/kg | Part B & C Cohort 2: AT-007 10mg/kg | Part B & C Cohort 3: AT-007 20mg/kg | Part B & C Cohort 4: AT-007 40mg/kg | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| t1/2 of AT-007 | 13.7 ± 45.3 | 22.0 ± 92.6 | 10.3 ± 31.7 | 8.42 ± NA | 8.2 ± 7.55 | 13.1 ± 39.5 | 15.7 ± 79.9 | 9.76 ± 22.4 | 9.96 ± 27.4 | 13.9 ± 11.0 | 16.8 ± 56.6 | 16.1 ± 21.1 |
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration
| microgram*hour/mL | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part B & C Cohort 1: AT-007 5mg/kg | Part B & C Cohort 2: AT-007 10mg/kg | Part B & C Cohort 3: AT-007 20mg/kg | Part B & C Cohort 4: AT-007 40mg/kg | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUClast of AT-007 | 12.6 ± 44.7 | 89.0 ± 18.5 | 158 ± 35.0 | 352 ± 75.0 | 624 ± 28.0 | 181 ± 44.3 | 311 ± 47.4 | 592 ± 26.9 | 1110 ± 50.2 | 172 ± 25.3 | 698 ± 21.8 | 1006 ± 62.3 |
Area under the plasma concentration-time curve from time zero extrapolated to infinity
| microgram*hour/mL | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg |
|---|---|---|---|---|---|---|---|---|
| AUCinf of AT-007 | 14.3 ± 43.7 | 81.8 ± 15.1 | 169 ± 35.3 | 163 ± NA | 655 ± 0.45 | 109 ± 28.2 | 518 ± 65.2 | 1327 ± 17.2 |
Disease-Specific Biomarker in Classic Galactosemia Patients
| maximal change from baseline in ng/mL | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension AT-007 20mg/kg | Part D Extension Placebo Comparator |
|---|---|---|---|---|---|---|
| Maximal Galactitol Reduction in Plasma | -475 ± 305 | -1175 ± 239 | -1259 ± 220 | -393 ± 239 | -974.4 ± 322.42 | -344.0 ± 449.67 |
Disease-Specific Biomarker in Classic Galactosemia Patients
| percent change from baseline | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension AT-007 20mg/kg Day 30 | Part D Extension AT-007 20mg/kg Day 60 | Part D Extension AT-007 20mg/kg Day 90 | Part D Extension Placebo Comparator Day 30 | Part D Extension Placebo Comparator Day 60 | Part D Extension Placebo Comparator |
|---|---|---|---|---|---|---|---|---|---|---|
| Galactose Concentration in Plasma | 8.94 ± 8.71 | -27.8 ± 29.3 | 25.4 ± 69.5 | 39.8 ± 62.7 | -153.78 ± 381.475 | 52.29 ± 170.753 | 30.42 ± 102.15 | 139.75 ± 273.418 | 98.67 ± 132.115 | 130.00 ± 101.059 |
Disease-Specific Biomarker in Classic Galactosemia Patients
| percent change from baseline | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension AT-007 20mg/kg Day 30 | Part D Extension AT-007 20mg/kg Day 60 | Part D Extension AT-007 20mg/kg Day 90 | Part D Extension Placebo Comparator Day 30 | Part D Extension Placebo Comparator Day 60 | Part D Extension Placebo Comparator |
|---|---|---|---|---|---|---|---|---|---|---|
| Galactose-1-Phosphate (Gal-1p) Concentration in Plasma | 5.71 ± 15.7 | 31.5 ± 6.78 | 7.86 ± 21.0 | 25.2 ± 8.74 | 33.1 ± 51.123 | 16.04 ± 43.218 | 4.87 ± 24.917 | 8.63 ± 24.473 | 14.03 ± 13.181 | 11.97 ± 21.511 |
Collected over Part A: 1 day; Part B&C: 7 days; Part D: 32 days; Part D Extension: 90 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Cohort 1: AT-007 0.5mg/kg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A Cohort 2: AT-007 5mg/kg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A Cohort 3: AT-007 10mg/kg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A Cohort 4: AT-007 20mg/kg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part A Cohort 5: 40mg/kg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part A Placebo Comparator | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Part B & C Cohort 1: AT-007 5mg/kg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part B & C Cohort 2: AT-007 10mg/kg | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part B & C Cohort 3: AT-007 20mg/kg | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Part B & C Cohort 4: AT-007 40mg/kg | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Part B & C Placebo Comparator | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part D Cohort 1: AT-007 5mg/kg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part D Cohort 2: AT-007 20mg/kg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part D Cohort 3: AT-007 40mg/kg | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part D Placebo Comparator | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part D Extension Cohort 1: 20mg/kg | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Part D Extension Cohort 2: 40mg/kg | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Part D Extension Placebo Comparator | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Event | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: 40mg/kg | Part A Placebo Comparator | Part B & C Cohort 1: AT-007 5mg/kg | Part B & C Cohort 2: AT-007 10mg/kg | Part B & C Cohort 3: AT-007 20mg/kg | Part B & C Cohort 4: AT-007 40mg/kg | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Cohort 1: 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension Placebo Comparator |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver InjuryHepatobiliary disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/8 | 0/10 | 0/9 | 0/8 | 0/4 | 0/4 | 0/4 | 0/6 | 1/9 | 0/2 | 0/4 |
| Event | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: 40mg/kg | Part A Placebo Comparator | Part B & C Cohort 1: AT-007 5mg/kg | Part B & C Cohort 2: AT-007 10mg/kg | Part B & C Cohort 3: AT-007 20mg/kg | Part B & C Cohort 4: AT-007 40mg/kg | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Cohort 1: 20mg/kg | Part D Extension Cohort 2: 40mg/kg | Part D Extension Placebo Comparator |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT IncreasedHepatobiliary disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 | 0/6 | 1/8 | 0/10 | 0/9 | 1/8 | 0/4 | 0/4 | 0/4 | 0/6 | 1/9 | 1/2 | 0/4 |
| Infections/InfestationsInfections and infestations | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 1/6 | 0/8 | 0/10 | 0/9 | 0/8 | 2/4 | 0/4 | 1/4 | 0/6 | 0/9 | 0/2 | 1/4 |
| Gastrointestinal DisordersGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/10 | 0/6 | 0/8 | 1/10 | 0/9 | 0/8 | 1/4 | 0/4 | 0/4 | 1/6 | 2/9 | 0/2 | 1/4 |
| Musculoskelatal & Connective Tissue DisordersMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 1/10 | 0/6 | 0/8 | 0/10 | 1/9 | 0/8 | 0/4 | 1/4 | 0/4 | 1/6 | 0/9 | 0/2 | 1/4 |
| Nervous SystemNervous system disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 2/10 | 0/6 | 0/8 | 1/10 | 0/9 | 1/8 | 0/4 | 1/4 | 0/4 | 1/6 | 1/9 | 0/2 | 0/4 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/8 | 2/10 | 0/9 | 0/8 | 1/4 | 0/4 | 0/4 | 0/6 | 0/9 | 0/2 | 0/4 |
| InvestigationsInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/10 | 0/6 | 1/8 | 0/10 | 0/9 | 1/8 | 0/4 | 0/4 | 1/4 | 0/6 | 1/9 | 0/2 | 0/4 |
| General DisordersGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/8 | 0/10 | 0/9 | 0/8 | 0/4 | 0/4 | 0/4 | 1/6 | 0/9 | 0/2 | 1/4 |
| Seasonal AllergiesImmune system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/8 | 0/10 | 0/9 | 0/8 | 0/4 | 0/4 | 0/4 | 0/6 | 1/9 | 0/2 | 0/4 |
| Reproductive System DisorderReproductive system and breast disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/8 | 0/10 | 0/9 | 0/8 | 0/4 | 0/4 | 0/4 | 0/6 | 1/9 | 0/2 | 0/4 |
| Age, Continuous(years) | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A Placebo Comparator | Part B & C AT-007 5mg/kg Cohort | Part B & C AT-007 10mg/kg Cohort | Part B & C AT-007 20mg/kg Cohort | Part B & C AT-007 40mg/kg Cohort | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg) | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: AT-007 40mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 42.5 (37 to 49) | 54.0 (47 to 58) | 35.0 (27 to 45) | 44.0 (39 to 52) | 31.5 (25 to 43) | 54.5 (39 to 64) | 32.5 (29 to 53) | 35.5 (30 to 40) | 35.0 (28 to 37) | 27.0 (23 to 37) | 37 (33 to 41.5) | 19.5 (18 to 21) | 37 (37 to 37) | 50 (50 to 50) | 19 (19 to 19) | 20.5 (19 to 22) | 28 (28 to 28) | 43 (43 to 43) | 32 (23 to 44) | 29.5 (20 to 41) | 22.0 (19 to 25) | 36.0 (22 to 50) | NA (NA to NA) |
| Sex: Female, Male(Participants) | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A Placebo Comparator | Part B & C AT-007 5mg/kg Cohort | Part B & C AT-007 10mg/kg Cohort | Part B & C AT-007 20mg/kg Cohort | Part B & C AT-007 40mg/kg Cohort | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg) | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: AT-007 40mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 5 | 2 | 4 | 4 | 8 | 5 | 3 | 4 | 5 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 3 | 3 | 0 | 56 |
| Male | 4 | 1 | 4 | 2 | 2 | 2 | 1 | 5 | 6 | 4 | 5 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 6 | 2 | 54 |
| Ethnicity (NIH/OMB)(Participants) | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A Placebo Comparator | Part B & C AT-007 5mg/kg Cohort | Part B & C AT-007 10mg/kg Cohort | Part B & C AT-007 20mg/kg Cohort | Part B & C AT-007 40mg/kg Cohort | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg) | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: AT-007 40mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 2 | 2 | 3 | 9 | 4 | 3 | 6 | 5 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43 |
| Not Hispanic or Latino | 5 | 1 | 4 | 4 | 3 | 1 | 2 | 5 | 4 | 4 | 5 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 4 | 4 | 9 | 2 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A Placebo Comparator | Part B & C AT-007 5mg/kg Cohort | Part B & C AT-007 10mg/kg Cohort | Part B & C AT-007 20mg/kg Cohort | Part B & C AT-007 40mg/kg Cohort | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg) | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: AT-007 40mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 2 | 3 | 2 | 1 | 1 | 4 | 3 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24 |
| White | 4 | 6 | 3 | 3 | 3 | 9 | 5 | 4 | 6 | 7 | 3 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 4 | 4 | 9 | 2 | 82 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A Placebo Comparator | Part B & C AT-007 5mg/kg Cohort | Part B & C AT-007 10mg/kg Cohort | Part B & C AT-007 20mg/kg Cohort | Part B & C AT-007 40mg/kg Cohort | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg) | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: AT-007 40mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 6 | 6 | 10 | 6 | 8 | 10 | 9 | 8 | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 4 | 4 | 9 | 2 | 110 |
| Galactitol(ng/mL) | Part A Cohort 1: AT-007 0.5mg/kg | Part A Cohort 2: AT-007 5mg/kg | Part A Cohort 3: AT-007 10mg/kg | Part A Cohort 4: AT-007 20mg/kg | Part A Cohort 5: AT-007 40mg/kg | Part A Placebo Comparator | Part B & C AT-007 5mg/kg Cohort | Part B & C AT-007 10mg/kg Cohort | Part B & C AT-007 20mg/kg Cohort | Part B & C AT-007 40mg/kg Cohort | Part B & C Placebo Comparator | Part D Cohort 1: AT-007 5mg/kg | Part D Cohort 1 (Placebo) Then Cohort 2 (AT-007 20mg/kg) | Part D Cohort 1 (AT-007 5mg/kg) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 1 (Placebo) Then Cohort 3 (AT-007 40mg/kg) | Part D Cohort 2: AT-007 20mg/kg | Part D Cohort 2 (AT-007 20mg/kg) Then Chort 3 (AT-007 40mg/kg) | Part D Cohort 3: AT-007 40mg/kg | Part D Placebo Comparator | Part D Extension Placebo Comparator | Part D Extension Cohort 1: AT-007 20mg/kg | Part D Extension Cohort 2: AT-007 40mg/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | — | — | — | — | — | — | — | — | — | — | — | 2490 (2200 to 2580) | 2380 (2380 to 2380) | 2140 (2140 to 2140) | 2360 (2360 to 2360) | 2170 (2060 to 2280) | 2340 (2340 to 2340) | 2810 (2810 to 2810) | 2480 (1995 to 3420) | 2612.5 (1960 to 3670) | 2300 (1780 to 2775) | NA (NA to NA) | 2434.4 (1950 to 3670) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Dec 2021, 29 months.
Results were first posted in May 2024, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Govorestat
Galactosemias
Applied Therapeutics, Inc.